February 12, 2020 / 8:29 AM / 8 days ago

BRIEF-Poxel Presents New Preclinical Results For PXL770

Feb 12 (Reuters) - POXEL SA:

* POXEL PRESENTS NEW PRECLINICAL PROOF-OF-CONCEPT RESULTS FOR PXL770 AT THE 3RD ANNUAL GLOBAL NASH CONGRESS

* POXEL SA SAYS CLINICAL RESULTS FROM PXL770 PK/PD TRIAL AND PHASE 2A STUDY EXPECTED IN 2Q AND 3Q OF 2020, RESPECTIVELY

* PXL770, OBSERVED TO REDUCE LIVER INFLAMMATORY CELLS, WHICH MAY CONTRIBUTE TO AN IMPROVEMENT OF FIBROGENESIS, IN A PRECLINICAL NASH MODEL

* WE NEAR UPCOMING CLINICAL READOUTS FROM OUR PXL770 PK/PD TRIAL AND PHASE 2A STUDY

* CLINICAL READOUTS FROM OUR PXL770 PK/PD TRIAL AND PHASE 2A STUDY, WHICH ARE CURRENTLY EXPECTED IN SECOND AND Q3 OF 2020, RESPECTIVELY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below